Concord Biotech Limited has successfully completed the acquisition of Celliimune Biotech Private Limited, securing a 100% stake in the company for Rs 66 lakh. This strategic move is designed to bolster Concord’s capabilities in pioneering DNA engineering for advanced cancer therapeutics and developing innovative alternatives to conventional chemotherapy, marking a significant step in the firm’s expansion into the biopharmaceutical research sector.
Strategic Investment in Biopharma
Concord Biotech Limited has finalized the acquisition of Celliimune Biotech Private Limited as of April 2, 2026. Through a cash consideration of Rs 66,00,000, Concord has acquired full ownership of the entity. This investment aligns with the company’s long-term objective to spearhead research in DNA engineering, focusing specifically on the discovery and development of next-generation solutions for cancer treatment.
Target Entity Overview
Celliimune Biotech, incorporated on January 15, 2025, operates within the biopharmaceutical industry and specializes in commercializing novel cell and gene therapy solutions. Prior to this acquisition, the target entity had nil turnover, reflecting its early-stage status as a research-focused organization. Concord Biotech intends to leverage this platform to innovate new therapies that provide superior alternatives to current chemotherapy practices.
Transaction Context
The transaction, which concluded on April 2, 2026, has been classified as an arm’s length deal. As a wholly-owned subsidiary, Celliimune will benefit from the operational scale and expertise of Concord Biotech, accelerating its research trajectory in the high-growth field of oncology and genetic therapeutics.
Source: BSE
